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AbstrACt
Introduction Post-traumatic stress disorder (PTSD) 
is a debilitating, highly prevalent condition. Current 
clinical practice guidelines recommend trauma-focused 
psychotherapy (eg, cognitive processing therapy; CPT) 
as the first-line treatment for PTSD. However, while 
these treatments show clinically meaningful symptom 
improvement, the majority of those who begin treatment 
retain a diagnosis of PTSD post-treatment. Perhaps for 
this reason, many individuals with PTSD have sought 
more holistic, mind–body, complementary and integrative 
health (CIH) interventions. However, there remains a 
paucity of high-quality, active controlled efficacy studies of 
CIH interventions for PTSD, which precludes their formal 
recommendation.
Methods and analyses We present the protocol for 
an ongoing non-inferiority parallel group randomised 
controlled trial (RCT) comparing the efficacy of a breathing 
meditation intervention (Sudarshan Kriya Yoga [SKY]) to a 
recommended evidence-based psychotherapy (CPT) for 
PTSD among veterans. Assessors are blinded to treatment 
group. The primary outcome measure is the PTSD 
Checklist-Civilian Version and a combination of clinical, 
self-report, experimental and physiological outcome 
measures assess treatment-related changes across each 
of the four PTSD symptom clusters (re-experiencing, 
avoidance, negative cognitions or mood and hyperarousal/
reactivity). Once the RCT is completed, analyses will use 
both an intent-to-treat (using the ‘last observation carried 
forward’ for missing data) and a per-protocol or ‘treatment 
completers’ procedure, which is the most rigorous 
approach to non-inferiority designs.
Ethics and dissemination To the best of our knowledge, 
this is this first non-inferiority RCT of SKY versus CPT 
for PTSD among veterans. The protocol is approved by 
the Stanford University Institutional Review Board. All 
participants provided written informed consent prior to 
participation. Results from this RCT will inform future 
studies including larger multi-site efficacy RCTs of SKY 
for PTSD and other mental health conditions, as well 
as exploration of cost-effectiveness and evaluation 
of implementation issues. Results will also inform 
evidence-based formal recommendations regarding CIH 
interventions for PTSD.
trial registration number NCT02366403; Pre-results.
IntroduCtIon
Post-traumatic stress disorder (PTSD) is a 
debilitating condition that develops in some 
individuals after exposure to a traumatic 
event. It is associated with four clusters of 
symptoms: (1) re-experiencing (eg, recur-
ring intrusive memories, flashbacks and 
disturbing dreams); (2) avoidance of stimuli 
associated with the trauma; (3) persistent 
negative alterations in cognitions and mood 
(eg, impaired memory, exaggerated shame/
guilt/blame, depression and anhedonia) and 
(4) altered arousal/reactivity (eg, irritability, 
aggression, hypervigilance, exaggerated 
startle, impaired attention/concentration 
and sleep disturbance).1 PTSD is associated 
strengths and limitations of this study
 ► There remains a paucity of high-quality, active 
controlled efficacy studies of complementary and 
integrative health interventions for post-traumatic 
stress disorder (PTSD).
 ► In response, here we present the protocol for an 
ongoing non-inferiority parallel group randomised 
controlled trial (RCT) comparing the efficacy of 
Sudarshan Kriya Yoga (SKY) breathing meditation 
to cognitive processing therapy for PTSD among 
veterans.
 ► The primary outcome measure is the PTSD 
Checklist-Civilian Version.
 ► Additional outcome measures (including experi-
mental and physiological) assess treatment-related 
changes across each of the four PTSD symptom 
clusters.
 ► This RCT is restricted to veterans; future RCTs 
will explore the efficacy of SKY in non-veteran 
populations.
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with poor quality of life and increased risk of suicide,2–4 
which may contribute to the alarming rise of suicidal 
behaviour among returning veterans.5 6 The lifetime 
prevalence of PTSD in the general US population is esti-
mated to be about 6.5%.7–9 Prevalence is reported to be 
up to 24.5% within veteran populations.10–12 Veterans 
with mental health disorders also have higher rates of 
comorbidity and greater severity of symptom presenta-
tion than non-veterans with mental health disorders.13 14 
A recent systematic review revealed that the median prev-
alence of PTSD in primary care (across civilian and 
veteran populations) is equivalent to that of depres-
sion,12 though it is not typically the primary referral or 
complaint,15 highlighting the need for rigorous educa-
tion, screening, assessment and appropriate treatment 
by providers.
Cognitive behavioural therapy (CBT), an evidence-
based psychotherapy, is considered the ‘gold standard’ 
(strongest evidence base) mental health intervention.16 
Current clinical practice guidelines for PTSD across 
national and international organisations, such as World 
Health Organisation (WHO), International Society for 
Traumatic Stress Studies, Veterans Affairs/Department 
of Defense (VA/DoD), American Psychiatric Association, 
National Institute for Clinical Excellence and Australian 
Centre for Posttraumatic Mental Health, all recommend 
trauma-focused therapy as the first-line treatment for 
PTSD.17–22 Trauma-focused therapy for PTSD includes 
variations of CBT, such as cognitive processing therapy 
(CPT), prolonged exposure therapy (PE) and imaginal 
exposure therapy (IE), as well as eye movement desensi-
tisation and reprocessing (EMDR). These evidence-based 
psychotherapies for PTSD show large effects compared 
with wait-list controls (average effect size=1.11)23 and 
supportive therapy (average effect size=1.01).24 They 
also have significantly higher effect sizes than medica-
tions, such as selective serotonin reuptake inhibitors 
(eg, sertraline), serotonin–norepinephrine reuptake 
inhibitors (eg, venlafaxine), atypical antidepressants (eg, 
nefazodone), alpha-1 blockers (eg, prazosin), antipsy-
chotics (eg, olanzapine and risperidone), tricyclic anti-
depressants and monoamine oxidase inhibitors (average 
effect size=0.43, n.s.).24
Despite the relative effectiveness of trauma-focused 
CBT as a treatment for PTSD, these evidence-based treat-
ments remain inadequate. First, although the majority 
of individuals receiving psychotherapy attain clinically 
meaningful symptom improvement, up to two-thirds of 
cases retain a PTSD diagnosis post-treatment.25 26 Second, 
treatment non-retention is a significant problem in mili-
tary-related PTSD treatment; several large studies in both 
the VA and the DoD found that only a small proportion 
of individuals receive a minimally adequate number of 
mental health encounters after PTSD diagnosis.27 Reasons 
for not seeking treatment and dropout are complex and 
include stigma, concerns about confidentiality, time 
demands, perceived treatment inefficacy and discomfort 
with the therapist.27
Perhaps as a result of the numerous problems 
surrounding currently available treatments, there is a 
trend for individuals with PTSD to seek more holistic, 
mind–body, complementary and integrative health (CIH) 
interventions.28 These CIH interventions (previously 
referred to as complementary and alternative medicine 
[CAM]) may be viewed as less stigmatising than formal 
mental health interventions, such as CBT.29 Recent data 
show that 34% of individuals within the general US popu-
lation30 and 39% of individuals with PTSD31 reported 
using at least one CIH intervention in the previous year. 
Outside of the PTSD field, a growing body of evidence 
underscores the efficacy of meditation/mindfulness-based 
CIH therapies for reducing suicidality32 and insomnia33 34 
and improving symptoms of anxiety and depression,35–42 
all of which overlap with PTSD, both in terms of diag-
nostic criteria and high frequency of comorbidities.1 2 43 44
Two recent systematic reviews and meta-analyses of 
randomised controlled trials (RCTs) concluded that 
CIH interventions significantly improve symptoms of 
PTSD. The larger of the two included 19 RCTs (mind-
fulness-based approaches [10 studies], meditation/
mantrum-based approaches [six studies], yoga-move-
ment based approaches [four studies] and combination 
approaches [one study]) and found support for a small–
medium effect size on PTSD, with effect sizes larger for 
smaller studies (<30 sample size).45 Similarly, the smaller of 
the two included 10 RCTs (mindfulness-based approaches 
[five studies], yoga-movement based approaches [three 
studies] and meditation/mantrum-based approaches 
[two studies]) and found support for a small–medium 
effect size on PTSD and depression.46 However, a consis-
tent theme across these systematic reviews and meta-anal-
yses is the paucity of high-quality, well-controlled efficacy 
studies of CIH interventions for PTSD, with existing 
studies containing biases, such as small sample size, inad-
equate control/comparison group, non-random allo-
cation, non-blinding, high attrition rates or a failure to 
report on these aspects of study design.
VA hospitals are mandated to provide certain CIH 
interventions (including meditation and yoga) that 
have preliminary evidence suggesting at least the poten-
tial for benefit.47 At the same time, the VA/DoD states 
that currently there is insufficient evidence to formally 
recommend CIH interventions as first-line treatments for 
PTSD.17 48 To inform a formal recommendation, studies 
must address the biases and poor quality highlighted 
in the two recent systematic reviews and meta-analyses 
outlined above. The ideal study design is a large RCT 
with an active control comparison group rather than 
case studies or non-controlled studies.49 Non-inferiority 
design RCTs are recommended for testing the hypothesis 
that a novel intervention (eg, a CIH intervention) is no 
worse than an established standard intervention (eg, trau-
ma-focused therapy) at treating the target condition (eg, 
PTSD).50 This design is particularly appropriate when 
the novel intervention may be preferable to the stan-
dard intervention for reasons other than efficacy, such as 
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lower costs, greater acceptability, lower dropout rates, etc. 
Sudarshan Kriya Yoga (SKY) is a promising CIH medita-
tion intervention for PTSD; it has been shown to reduce 
symptoms of PTSD, depression and anxiety in several 
uncontrolled or small pilot RCTs, including several 
involving veterans with a history of trauma.51–55 Our clin-
ical research team at the VA Palo Alto Health Care System 
recently launched a RCT with a non-inferiority parallel 
group design comparing a breathing meditation inter-
vention (SKY) to an evidence-based psychotherapy (CPT) 
for PTSD in veterans (‘Breathing Meditation Interven-
tion for Post-Traumatic Stress Disorder’ [PI Bayley]; VA 
RR&D Merit Review;  ClinicalTrials. gov). The aim of this 
manuscript is to outline the study design and protocol for 
this ongoing, 4-year RCT. The primary aim of the RCT 
is to test the hypothesis that SKY breathing meditation 
is non-inferior to CPT as a treatment for veterans with 
clinically significant symptoms of PTSD. As such, we will 
compare PTSD symptoms pre-treatment versus post-treat-
ment, as well as pre-treatment versus 1-month and 1-year 
follow-up. We also aim to assess whether dropout rates 
at post-treatment differ between SKY and CPT. The 
secondary aim is to explore the potential differences in 
mechanisms of treatment action; for example, SKY may 
work via bottom-up (physiological arousal and regula-
tion) processes whereas CPT may exert more top-down 
(cognitive and self-regulatory) influences. As this aim 
is exploratory, we do not have directional hypotheses; 
however, we have carefully chosen a combination of clin-
ical interview, self-report, experimental and physiological 
outcome measures to assess differential treatment-related 
changes across each of the four PTSD symptom clusters 
of re-experiencing, avoidance, negative cognitions or 
mood and hyperarousal/reactivity (figure 1).
MEthods And AnAlysEs
Patient and public involvement
In May 2016, the VA issued a memorandum entitled 
‘Advancing Complementary and Integrative Health in 
VHA’, mandating that all VA hospitals provide CIH inter-
ventions—such as meditation and yoga—to Veterans,47 
emphasising the VA’s commitment to providing these 
services. The memorandum was jointly authored by Tracy 
Gaudet, MD, Director, Office of Patient Centered Care 
& Cultural Transformation, and David J Shulkin, MD, 
then Under Secretary for Health. The Office of Patient 
Centered Care & Cultural Transformation is charged 
with transforming the VA Health Care System into a 
patient-centred, patient-driven, personalised approach. 
This RCT is in direct alignment with this memorandum.
study design
A non-inferiority parallel group design RCT is being used 
to test the hypothesis that SKY breathing meditation is 
non-inferior to CPT as a treatment for veterans with clini-
cally significant symptoms of PTSD. Participants who meet 
inclusion criteria are randomly assigned to one of two 
groups (SKY or CPT) and receive treatment over a 6-week 
period. Random allocation occurs at a 1:1 (SKY:CPT) 
ratio and participants blindly draw their group out of a 
hat consisting of sealed envelopes created by the study 
coordinator. The primary outcome measure is change in 
PTSD symptoms, as measured by the PTSD Checklist-Ci-
vilian Version (PCL-C) and assessed at pre-treatment, 
post-treatment, 1-month follow-up and 1-year follow-up. 
The PCL-C was chosen as the primary outcome measure 
over a clinical diagnostic interview (eg, Clinician-Admin-
istered PTSD Scale for DSM-5 [CAPS-5]) for the following 
reasons: (1) it can be administered over the telephone 
making it ideal for screening and follow-up and thus, 
avoiding additional in-person visits by participants; (2) 
it has excellent psychometric properties including high 
convergent validity (r=0.93) with the CAPS56–59 and (3) 
it was the primary outcome measure in a previous pilot 
study of SKY for PTSD;52 thus, allowing for comparability 
of findings across studies.
The secondary outcome measures utilise a multi-meth-
odological exploratory approach assessing a wide range 
of subjective and objective PTSD-related symptoms 
Figure 1 Graphical representation of outcome measures by post-traumatic stress disorder symptom clusters. BDI-II, Beck 
Depression Inventory II; BSS, Beck Scale for Suicide Ideation; CANTAB, Cambridge Neuropsychological Test Automated 
Battery; CAPS, Clinician-Administered PTSD Scale for DSM-5 past month version; PANAS, Positive and Negative Affect 
Schedule; PCL, Post-traumatic Stress Disorder Checklist; PTSD, post-traumatic stress disorder.
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assessed pre-treatment and post-treatment. This combi-
nation of clinical interview, self-report, experimental and 
physiological outcome measures were chosen to assess 
treatment-related changes across each of the four PTSD 
symptom clusters of re-experiencing, avoidance, negative 
cognitions or mood and hyperarousal/reactivity1 (table 1, 
figure 1).
setting
All in-person assessments and treatment interventions 
occur at the War Related Illness and Injury Study Center 
at the Veterans Affairs Palo Alto Health Care System 
(VAPAHCS) in Palo Alto, California, USA. All screening 
interviews, assessments and the CPT intervention are 
conducted in private clinical interview rooms. The SKY 
intervention is conducted in a large conference room.
Participants
This RCT is funded by the Department of Veterans Affairs 
RR&D Merit Review (‘Breathing Meditation Intervention 
for Post-Traumatic Stress Disorder’ [PI Bayley];  Clini-
calTrials. gov) and the RCT is only open to veterans. To 
ensure the greatest generalisability for dissemination of 
meditation for treating PTSD, participants are any veteran 
of any age or sex who demonstrate clinically significant 
symptoms of PTSD. Participants are community-dwelling 
outpatient adult veterans who reside in the San Francisco 
Bay Area and those from outer areas who are willing and 
able to visit the VA Palo Alto for assessment and treat-
ment. A recent study among Vietnam veterans suggests 
that most ethnic minority veteran groups have a higher 
rate of PTSD than Caucasian veterans.60 Therefore, we 
are seeking an ethnically diverse population of male and 
female veterans, with combat and non-combat PTSD.
Exclusion criteria
Individuals are excluded if they (1) are participating in 
a concurrent treatment study; (2) are unable to attend 
study visits and sessions at the VA Palo Alto; (3) intend to 
begin a new trauma-focused therapy (eg, CPT, PE, IE and 
EMDR) during the study period; (4) have experienced 
mania or psychosis for any reason within the past 6 months 
(eg, bipolar, schizophrenia and drug-induced psychosis, 
as the effects of SKY on more severe mental health disor-
ders are unknown); (5) endorse suicidal or homicidal 
intent within the past 60 days (those that do are referred 
for VA psychiatric care); (6) endorse substance depen-
dence (other than nicotine) within the past 30 days; (7) 
have an unmanaged seizure disorder; (8) have a severe 
traumatic brain injury or (9) have initiated psychotropic 
medication within 8 weeks prior to screening (all medica-
tion use is closely tracked throughout the duration of the 
RCT). Study candidates who express imminent intent to 
harm self or others at any point in the study are referred 
for VA emergency care. Participants who exhibit clinically 
meaningful symptoms of PTSD but are eliminated due 
to screening failure, or elect not to participate in this 
research programme, are referred to their local mental 
health clinic.
Sample size (power analysis)
The minimum clinically meaningful difference on 
the PCL-C is estimated to be 10-points61 62 and is the 
threshold criterion to determine whether SKY reaches 
non-inferiority to CPT (while some PTSD treatment 
studies have used non-inferiority thresholds of 10-points 
on the CAPS,50 treatment-related changes on the CAPS 
are typically two-thirds to three quarters of those observed 
Table 1 Outcome measures and assessment time points
Measure Phone screen On-site screen Pre-treatment Post-treatment 1-month follow-up 1-year follow-up
PCL-5* x
MINI* x
PCL-C x x x x
CAPS-5* x x 
BDI-II x x
BSS x x
PANAS x x x x
CANTAB x x
Actigraphy x x
Heart rate x x
MAPI x x
RLS-DI* x x 
*Proctored.
BDI-II, Beck Depression Inventory II; BSS, Beck Scale for Suicide Ideation; CANTAB, Cambridge Neuropsychological Test Automated 
Battery; CAPS-5, Clinician-Administered PTSD Scale for DSM-5 past month version; MAPI, Multivariate Apnea Prediction Index; MINI, Mini-
International Neuropsychiatric Interview; PANAS, Positive and Negative Affect Schedule; PCL-5, Post-traumatic Stress Disorder Checklist-
Version 5; PCL-C, Post-traumatic Stress Disorder Checklist-Civilian Version; RLS-DI, Restless Legs Syndrome-Diagnostic Index.
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on the PCL,61 so our choice of a 10-point threshold on the 
PCL-C is conservative). In a large study of 374 veterans 
with PTSD treated with CPT, the mean change in PCL 
scores following treatment was 18.9 (SD=12.3 [Dr K 
Chard, personal communication]).63 As recommended 
for non-inferiority trials, we set the power to 80% and 
type I error to p=0.025.50
When designing the study protocol, dropout rates from 
PTSD treatment studies delivering CPT ranged from 17% 
to 22% in non-VA studies25 and were approximately 20% 
in VA studies.64 A pilot study of SKY for PTSD reported a 
dropout rate of 9% (1 of 11 veterans) at 1-year follow-up.52
Power analyses determined that a minimum of 30 
participants per group are needed. We took the highest 
(most conservative) dropout rate of 22% and aimed to 
recruit a total of 76 participants (n=38 per group), which 
should allow for the minimum of n=30 per group at 1-year 
follow-up. However, more recent PTSD treatment studies 
have higher dropout rates (25%–30%).26 65 Therefore, if 
our study has high dropout, we will continue to recruit 
participants until we reach the appropriately powered 
number of 30 participants per treatment group (consis-
tent with previous RCTs of PTSD, we define treatment 
dropout as completion of <75% of the treatment sessions 
for either CPT or SKY66).
recruitment
Participants are recruited through a multifaceted outreach 
strategy including direct outreach to veterans, clinician 
referral, direct mail and local advertisements. Study 
staff coordinate mass mailing of a flyer to local veterans 
who have reported symptoms of PTSD, give presenta-
tions about the study to veterans at various outpatient 
and community groups, liaise with clinicians to educate 
them about the study and obtain referrals, host informa-
tion desks at VAPAHCS and post flyers at VAPAHCS and 
surrounding community-based outpatient clinics.
Procedure
Initial screening is performed by the study coordinator 
over telephone using the PCL-5 to confirm presence/
absence of clinically meaningful symptoms of PTSD. 
The PCL-5 is a 20-item self-report measure that assesses 
current PTSD symptom severity according to the Diag-
nostic and Statistical Manual of Mental Disorders (fifth ed; 
DSM-5) diagnostic criteria.67 When this RCT commenced, 
the PCL-5 had only recently been released and a clinical 
cut-off score of 38 was proposed (which we are imple-
menting here). Psychometrics were recently completed, 
and a clinical cut-off score of 31–33 is now recommended 
as having the highest convergent validity with the CAPS-
5.68 69 Therefore, our screening cut-off score of 38 is a 
conservative estimate of clinically meaningful symptoms 
of PTSD. Candidates who meet this criteria are given an 
appointment at the study site in which the study coordi-
nator administers the Mini International Neuropsychiatric 
Interview (MINI 7.0)70 to assess exclusion criteria. Eligible 
participants are guided through informed consent (RCT 
participation, data collection and future contact for other 
research studies) by the study coordinator and complete 
demographic and health histories. Each participant then 
undergoes a pre-treatment assessment and is randomly 
assigned to one of two treatment groups. Participants are 
also assessed at post-treatment, 1-month follow-up and 
1-year follow-up (figure 2). Pre-treatment and post-treat-
ment assessments require visits on consecutive days and 
an overnight assessment in between. Participants have 
the option of overnight accommodation in a local hotel 
to enable them to conveniently undergo the evening and 
morning assessments. Participants are reimbursed for 
their participation in the study, with half of the payment 
made at the post-treatment visit and the other half made 
at the end of the 1-year follow-up.
Interventions
Cognitive processing therapy (CPT)
CPT is an evidence-based, trauma-focused CBT. It has 
been shown to be as efficacious as PE in treating PTSD 
and comorbid symptoms of depression,71 with effects 
maintained at least 5–10 years post-treatment.72 Sessions 
are rigorously structured, with content, materials and 
home practice assignments dictated by a manual.73 74 CPT 
consists of twelve 50–60 min sessions given twice per week 
for a duration of 6 weeks. Sessions focus on developing 
cognitive ‘restructuring’ skills and then applying them 
to challenge negative beliefs (‘stuck points’) related to 
responsibility for the traumatic event(s) and five addi-
tional key areas (safety, trust, power/control, esteem and 
intimacy) (table 2). Home practice is assigned following 
each session, and a significant amount of in-session time 
is spent reviewing home practice. All CPT sessions are 
delivered by a licensed or postdoctoral clinical psychol-
ogist trained in CPT. All CPT providers were certified 
via the VA’s CPT rollout initiative. Sessions are audio 
recorded to determine adherence. (Note that for this 
RCT, we are employing the ‘cognitive only’ version of 
CPT, which does not include a written account of the 
trauma. The manual we are using refers to this version as 
‘CPT-C’73 74; however, the latest version of the manual75 
now uses the term ‘CPT’ to refer to the version that does 
not include a written trauma account (ie, the previous 
‘CPT-C’), whereas ‘CPT-A’ now refers to the version that 
includes the written trauma account (ie, the previous 
‘CPT’). This change in terminology and standard prac-
tice stems from the dismantling study conducted in 2008 
that demonstrated equivalent efficacy in treating PTSD 
between both versions of CPT (with/without the written 
trauma account), though the version without the written 
trauma account demonstrated faster symptom improve-
ment across the 6 weeks of treatment and lower dropout 
rates than the version with the written trauma account 
(22% vs 34%)76
Sudarshan Kriya Yoga (SKY)
SKY is provided in a group format and incorporates 
controlled cyclical breathing exercises, gentle yoga 
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postures and periods of discussion (Project Welcome Home 
Troops; www. pwht. org). It has been shown to reduce symp-
toms of PTSD, depression and anxiety in individuals 
with a history of trauma,51–55 with effects maintained at 
6 months51 54 and 1 year52 post-treatment. SKY proto-
cols used in research typically consist of three different 
controlled breathing techniques, performed in a seated 
position, eyes closed or gaze focused down, breathing 
through the nostrils: (1) three-stage victory breath (ujjayi 
pranayama); (2) bellows breath (bhastrika pranayama); and 
(3) SKY breath (Sudarshan Kriya). (We use the non-San-
skrit names (alternate nostril breath, victory breath, 
bellows breath, SKY breath and straw breath) in groups 
to allow greater accessibility to veterans, consistent with 
Project Welcome Home Troops and the International Associa-
tion of Human Values [IAHV].). Sudarshan Kriya—the 
central component of SKY—is a cyclical breathing exer-
cise consisting of consecutive slow, medium and fast 
breath cycle rates. Victory breath and bellows breath are 
practised in many schools of yoga, though the number 
and rate of breath vary. Sessions close with a meditation/
rest phase (shavasana). The in-session version of SKY 
contains a longer version of the SKY breath and is instruc-
tor-led for safety. The home practice version contains a 
shorter version of the SKY breath (with the option to use 
a guided audio CD), classical yoga stretches and a guided 
meditation.
We use a SKY protocol designed by Project Welcome Home 
Troops specifically tailored for veterans and adapted for 
clinical purposes. The protocol consists of a 5-day inten-
sive group workshop (3 hours per day) (table 3) followed 
by ten 60 min sessions given twice per week (alternating 
between a longer instructor-led [full SKY protocol] 
version and the shorter home practice version [in-ses-
sion, instructor-led]) for a duration of 5 weeks. This 
Project Welcome Home Troops SKY protocol differs from the 
contemporary standard SKY protocol in which: (1) the 
initial intensive workshop is 5 days versus 3 days to allow 
for gradual introduction of the SKY breath (delivered on 
Days 4 and 5 instead of Days 1–3); thus, permitting initial 
development of foundational breathing and meditation 
techniques; (2) alternate nostril breath (nadi sodhana) 
and straw breath (deep breaths inhaled through the nose 
and exhaled through the mouth with pursed lips, as if 
breathing through a straw) are taught and practised at 
the beginning and end of sessions, respectively, and (3) 
two instructors trained in military culture facilitate the 
course with an emphasis on resilience, empowerment, 
connection and reintegration post-service.
The SKY treatment is a total of 6 weeks long and, after 
the initial intensive workshop, is equivalent in frequency 
and duration to the CPT treatment. SKY, however, involves 
25 hours of group contact time, which is greater than 
CPT’s 12 hours of contact time, though CPT is arguably 
more ‘concentrated’ as participants receive one-on-one 
treatment. In designing the RCT, we deemed that equiva-
lent duration (ie, 6 weeks) was most crucial for determining 
non-inferiority of SKY versus CPT (the primary hypoth-
esis), as treatment dropout often increases over time. The 
Project Welcome Home Troops SKY protocol involves an initial 
5-day intensive group 'retreat', so this feature could not 
be altered. If non-inferiority of SKY compared with CPT 
is suggested, subsequent studies could and should investi-
gate questions regarding dosage and duration.
Figure 2 CONSORT flow diagram. CONSORT; Consolidated Standards of Reporting Trials.
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Home practice is optional and strongly encouraged. 
All SKY sessions are led by an experienced, certified SKY 
instructor from Project Welcome Home Troops , a project of 
IAHV ( www. iahv. org). As some breathing components 
have important contraindications, such as pregnancy, 
high blood pressure or seizures. SKY should only be 
taught by experienced instructors trained in appropriate 
delivery and individual modification. Sessions are video 
recorded to determine adherence.
outcome measures
PTSD Checklist-Civilian Version (PCL-C)
The PCL-C77 is a 17-item self-report measure that assesses 
current PTSD symptom severity corresponding to the 
DSM-IV diagnostic criteria for PTSD.78 It is the primary 
outcome measure (see Study design). Responses to indi-
vidual items related to the four symptom clusters will also 
be used for the secondary exploratory analyses. (Due to 
our non-inferiority design, it is crucial for the primary 
outcome measure to have an established margin of a clin-
ically meaningful change. At the time of commencement 
of this RCT, the psychometric properties of the newer 
PCL-5 were unknown.)
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) past 
month version
The CAPS-579 is the gold standard semi-structured clinical 
diagnostic interview for the assessment of PTSD.80 CAPS-5 
items correspond to DSM-51 symptom definitions. It is a 
secondary clinical outcome measure to confirm PTSD 
diagnostic status and severity. Responses to individual 
items related to the four symptom clusters will also be 
used for the secondary exploratory analyses.
Mini-International Neuropsychiatric Interview (MINI 7.0)
The MINI 7.070 is a brief (15 min) structured clinical 
interview designed to screen for current and lifetime 
DSM-5 and International Classification of Diseases (ICD-
10) mental health disorders. It is being used here to assess 
exclusion criteria (ie, mania, psychosis and substance 
dependence [see Participants]).
Beck Depression Inventory II (BDI-II)
The Beck Depression Inventory-II81 is a 21-item self-re-
port measure that assesses current depression symptom 
severity (negative alterations in mood symptom cluster). 
Items are rated on a four-point scale according to how 
much the symptom bothered the respondent over the 
prior 2 weeks.
Beck Scale for Suicide Ideation (BSS)
The  BSS82 is a 21-item self-report measure that assesses 
the extent of thought, planning and intent to engage 
in self-directed harm over the past week (negative alter-
ations in mood symptom cluster).
Positive and Negative Affect Schedule (PANAS)
The PANAS83 is a 20-item self-report measure that assesses 
positive and negative mood states (negative alterations in 
Table 3 Summary of session content for Sudarshan Kriya 
Yoga (SKY)
Session Content Daily home practice






















6, 8, 10 
and 12
SKY breathing and 
accompanying practices
30 min breathwork 
daily
7, 9, 11 
and 13
SKY home practice 
programme
Guided meditation
30 min breathwork 
daily
Table 2 Summary of session content for cognitive 
processing therapy (CPT)
Session Content Home practice assignment
1 Introduction and 
education phase
Describe event’s impact
2 Meaning of the event ABC worksheets
3 Identifying thoughts 
and feelings
ABC worksheets




5 Challenging questions Identify problematic thinking 
patterns
6 Problematic thinking Practice challenging beliefs
7 Challenging beliefs Evaluate safety beliefs
8 Safety issues Evaluate trust beliefs
9 Trust issues Evaluate power/control 
beliefs
10 Power/control issues Evaluate esteem beliefs
Give/receive compliments
Pleasant/positive activities





12 Intimacy issues; 
revisiting meaning of 
the event
Continue using worksheets
ABC worksheets, preliminary cognitive restructuring exercise 
involving identification of Activating event, Belief and 
Consequences of belief.
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mood symptom cluster). Items are rated on a five-point 
Likert scale according to the extent to which participants 
experienced each of 20 emotions over the past few weeks.
Daily sleep and home practice compliance log
Participants record an estimate of the duration of their 
sleep each night (altered arousal symptom cluster) and 
the extent to which they complete their assigned home 
practice each day.
Cambridge Neuropsychological Test Automated Battery (CANTAB)
The CANTAB (Cambridge Cognition; www. cambridgecog-
nition. com) is a computerised neuropsychological assess-
ment system. It is the most well-validated and widely used 
cognitive research software.84–88 We utilise tasks assessing 
learning, visual memory, spatial working memory and 
sustained attention (negative alterations in cognition and 
altered reactivity symptom clusters).
Actigraphy
Participants wear a Motionlogger Actigraph (Ambulatory 
Monitoring, Inc.) wristwatch overnight at pre-treatment 
and post-treatment that records ambulatory movement to 
measure sleep patterns (altered arousal symptom cluster). 
It provides an objective, robust and valid measure of sleep 
quality, including total sleep time, sleep onset and wake-
fulness.89 90
Heart rate
Participants wear the ActiWave (CamNtech) heart rate 
monitor on their chest overnight at pre-treatment and 
post-treatment to assess physiological arousal (altered 
arousal symptom cluster).91 92
Multivariate Apnea Prediction Index (MAPI)
The MAPI93 is a 13-item self-report measure that yields 
a percentage likelihood that each participant has clini-
cally meaningful sleep apnea. This measure will be used 
to ensure the actigraphy sleep data are not confounded 
by artefacts due to sleep apnea.
Restless Legs Syndrome-Diagnostic Index (RLS-DI)
The RSL-DI94 is a standardised diagnostic tool developed 
from a combination of data from polysomnography, 
neurological reports and clinical interviews to diagnose 
restless legs syndrome according to current international 
diagnostic criteria. This measure will be used to ensure 
the actigraphy sleep data are not confounded by artefacts 
due to restless legs syndrome.
data collection and blinding
All in-person assessments (ie, clinical interviews, outcome 
measures and experimental assessments) are conducted 
by an assessor blinded to treatment group (SKY and CPT) 
to protect the integrity of assessment and prevent assessor 
bias. Data entry is also blinded and data collection is 
ongoing. Data are de-identified and stored on the secure 
VA network and REDCap. Demographics information is 
stored separately from data on the secure VA network and 
are password protected to ensure confidentiality. No anal-
yses will occur prior to the completion of the RCT and 
closure to recruitment. Once the RCT is completed, data 
analysis will be conducted by a statistician blind to treat-
ment group. Long-term access to the final RCT dataset 
will be maintained by the principal investigator (PJB).
data analysis plan
The RCT will employ a 2 group (SKY and CPT) × 4 time 
(pre-treatment, post-treatment, 1-month follow-up and 
1-year follow-up) design for each outcome measure. 
Primary analyses will use both an intent-to-treat (ITT) 
data sample (ie, all randomised participants, including 
those who dropout) and a per-protocol or ‘treatment 
completers’  procedure (ie, only participants who 
complete the protocol/treatment). Consistent with 
previous RCTs of PTSD, we define treatment completers 
as those who complete ≥ 75 % of the treatment sessions 
for either CPT or SKY. 66 In the ITT analyses, we will 
use the ‘last observation carried forward’ method-
ology, which is considered a conservative approach for 
handling missing data.95–98 In a non-inferiority design, 
ITT favours the alternative hypothesis (ie, no difference 
between treatments), because it minimises the difference 
between groups; therefore, using both analyses (ITT and 
per-protocol/treatment completers) is the most rigorous 
approach to non-inferiority designs.50 Lowering the alpha 
level to correct for multiple comparisons is not appro-
priate in non-inferiority designs as it has the same effect 
as increasing the alpha level in traditional (superiority) 
designs. We will use both 95% CI and hypothesis testing 
(one-sided t-test; α=0.025) to compare the mean change50 
in outcome measure scores from pre-treatment to 
post-treatment for the SKY versus CPT treatment groups.
Randomisation allows for an unbiased distribution of 
potential confounding variables and as such, the two 
treatment groups (SKY and CPT) are not expected to 
differ on key demographic variables (eg, age, sex, race, 
ethnicity, education, PTSD severity, psychiatric comor-
bidity and medication use). However, if significant group 




The protocol is approved by the  Stanford University 
Institutional Review Board. All participants have provide 
written informed consent prior to participation (see 
online supplementary appendices). Consent forms are 
audited annually by the VA. Annual continuing reviews 
are also conducted by the Stanford University Insti-
tutional Review Board (IRB) and the Department of 
Veterans Affairs.
safety policy
All participants are routinely followed-up by telephone by 
the study coordinator (JST) to monitor serious adverse 
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events and unanticipated problems. Any serious adverse 
events and unanticipated problems will be recorded 
and reported to the Stanford University IRB and the VA 
within the reporting deadlines. No additional data safety 
and monitoring board were required by the IRB. Suicide 
risk is comprehensively assessed throughout the study 
and a safety plan exists (led by a licensed clinical psychol-
ogist; RJS-H) to be employed in respond to reports of 
thoughts about or intent to harm oneself or others. The 
interviewer will assess whether the participant has a viable 
plan and means to carry out the plan.
dissemination policy
The datasets generated and/or analysed during the 
current study are not publicly available due to privacy 
restrictions at the Department of Veterans Affairs. 
De-identified electronic datasets will be made available 
on written request to the principal investigator (PJB). 
Once the RCT is completed, outcomes will be published 
in international peer-reviewed journals, regardless of the 
direction of effects.
trial registration
This RCT was first registered online at  ClinicalTrials. gov 
on 19 February 2015. The first participant was recruited 
in March 2016. Recruitment is expected to continue until 
March 2019 with 1-year follow-up to be completed in 
March 2020.
dIsCussIon
PTSD is a debilitating, highly prevalent condition in both 
general and veteran populations.2–4 7–12 Current national 
and international clinical practice guidelines recommend 
evidence-based, trauma-focused psychotherapy (eg, CPT, 
PE, IE and EMDR) as the first-line treatment for PTSD.17–22 
Despite the relative success of these treatments,23 24 the 
majority of those who begin treatment retain a diagnosis 
of PTSD post-treatment.25 26 For these and other reasons 
(eg, personal preference, stigma, accessibility to treat-
ment and cost-effectiveness) healthcare consumers and 
providers have begun to seek more holistic, mind–body, 
CIH interventions for a variety of conditions.28 However, 
there remains a paucity of high-quality, active controlled 
efficacy studies of CIH interventions for PTSD, which 
precludes their formal recommendation by institutions, 
such as the VA and the DoD.17
The aim of this RCT is to address this gap in the field. 
Here, we present the protocol for an ongoing, 4-year 
non-inferiority parallel group design RCT comparing the 
efficacy of SKY (a breathing meditation intervention) to 
CPT (an evidence-based psychotherapy) for treating PTSD 
among veterans. If non-inferiority of SKY compared with 
CPT is suggested then this will provide an empirical ratio-
nale for a larger multi-site RCT to evaluate the efficacy of 
SKY in multiple treatment settings across different veteran 
populations. This will also provide the impetus to explore 
cost-effectiveness of SKY versus trauma-focused therapy, 
evaluate implementation issues (eg, setting [hospital vs 
community centre], target population demographics (eg, 
veteran vs non-veteran) and investigate the efficacy of SKY 
for other mental health conditions with high comorbidity 
with PTSD (eg, depression, chronic pain and substance 
use). Such a study would inform evidence-based formal 
recommendations regarding the implementation of CIH 
interventions in the VA Health Care System. Results from 
the secondary analyses exploring potential differences 
in mechanisms of treatment action may inform future 
studies focused on the individuality of care (ie, precision 
medicine).
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